CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Rating of “Hold” by Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have earned a consensus rating of “Hold” from the nineteen research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $78.38.

Several analysts recently issued reports on the stock. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Chardan Capital reissued a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Bank of America decreased their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Finally, Needham & Company LLC restated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, January 14th.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $41.51 on Wednesday. The company’s 50-day moving average is $44.72 and its two-hundred day moving average is $47.99. The firm has a market capitalization of $3.54 billion, a price-to-earnings ratio of -14.67 and a beta of 1.68. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same period in the prior year, the business posted ($1.41) earnings per share. As a group, equities analysts anticipate that CRISPR Therapeutics will post -5.13 earnings per share for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the sale, the chief executive officer now owns 196,540 shares in the company, valued at $10,931,554.80. The trade was a 13.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.10% of the stock is currently owned by corporate insiders.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Capital Market Strategies LLC acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $461,000. Capital Advisors Inc. OK boosted its holdings in shares of CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock valued at $14,122,000 after acquiring an additional 22,583 shares during the period. Geode Capital Management LLC grew its position in shares of CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after acquiring an additional 35,196 shares during the last quarter. Granite Bay Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at $2,375,000. Finally, State Street Corp raised its position in CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.